BioNexus Gene Lab Corp.
BGLC Basic Materials Specialty Chemicals
BioNexus Gene Lab Corp.’s revenue for fiscal 2025 (year ended December 2025) was $7.4 million, down 21.9% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS grew 64.7% and free cash flow grew 44.3%, each against the same quarter a year earlier.
Follow BGLC
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
1.26 | 0.86 | 2.79 | 2.12 | 2.12 | 5.93 | 4.38 | 4.04 |
Receivables |
0.02 | 0.02 | 4.02 | 3.44 | 2.93 | 0.98 | 1.66 | 0.65 |
Inventory |
0.02 | 0.01 | 1.18 | 1.52 | 0.98 | 1.14 | 1.39 | 0.68 |
Other current assets |
0.02 | 0.01 | 0.02 | 0.08 | 0.03 | — | — | 0.08 |
Total current assets |
1.30 | 0.88 | 7.99 | 7.15 | 6.02 | 8.05 | 7.43 | 5.45 |
Property, Plant, Equpment (Net) |
0.34 | 0.31 | 1.79 | 1.63 | 1.51 | 1.51 | 1.52 | 1.60 |
Long-Term Investments |
0.01 | 0.01 | 0.28 | 0.75 | 1.15 | 1.70 | 1.27 | 2.03 |
Total non-current assets |
0.35 | 0.35 | 2.13 | 2.42 | 2.72 | 3.35 | 3.00 | 3.80 |
Total Assets |
1.65 | 1.23 | 10.12 | 9.57 | 8.74 | 11.40 | 10.43 | 9.25 |
Accounts Payable |
— | — | 3.17 | 2.01 | 1.86 | 1.40 | 1.50 | 0.00 |
Current Part of Capital Lease |
0.02 | 0.02 | 0.03 | 0.02 | 0.02 | 0.03 | 0.05 | 0.06 |
Current Part of Taxes to Pay |
0.03 | — | 0.06 | 0.10 | — | — | — | — |
Current Revenue (Deferred) |
— | — | — | 0.08 | — | — | — | — |
Other current liabilities |
0.01 | 0.02 | 0.10 | 0.18 | 0.13 | 0.01 | 0.02 | 0.05 |
Total current liabilities |
0.06 | 0.05 | 3.37 | 2.33 | 2.00 | 1.63 | 1.95 | 0.52 |
Long Term Debt (Total) |
0.06 | 0.05 | 0.04 | 0.01 | — | — | — | — |
Long Term Tax Liability (Deferred) |
0.00 | — | 0.00 | 0.03 | 0.03 | 0.01 | — | — |
Total non-current liabilities |
0.07 | 0.06 | 0.08 | 0.07 | 0.07 | 0.11 | 0.16 | 0.12 |
Total liabilities |
0.13 | 0.11 | 3.45 | 2.39 | 2.08 | 1.74 | 2.11 | 0.64 |
Additional Paid In Capital |
(5.01) | (5.01) | (5.01) | (5.01) | (5.01) | (5.01) | (5.01) | (5.01) |
Common Stock (Net) |
6.65 | 6.48 | 10.78 | 10.78 | 10.93 | 17.19 | 17.33 | 20.17 |
Retained Earnings |
(0.09) | (0.33) | 0.76 | 1.51 | 1.16 | (1.84) | (3.44) | (6.43) |
Common Equity (Total) |
1.52 | 1.12 | 6.66 | 7.18 | 6.67 | 9.66 | 8.32 | 8.61 |
Shareholders Equity (Total) |
1.52 | 1.12 | 6.66 | 7.18 | 6.67 | 9.66 | 8.32 | 8.61 |
Shareholders Equity and Liabilities (Total) |
1.65 | 1.23 | 10.12 | 9.57 | 8.74 | 11.40 | 10.43 | 9.25 |
Shares (Common) |
0.62 | 0.86 | 1.43 | 1.43 | 1.45 | 17.67 | 1.80 | 2.42 |
Shareholders Equity (Tangible) |
1.52 | 1.12 | 6.66 | 7.18 | 6.67 | 9.66 | 8.32 | 8.61 |
Net Debt |
(1.20) | (0.81) | (2.75) | (2.11) | (2.12) | (5.93) | (4.38) | (4.04) |
Total Debt |
0.06 | 0.05 | 0.04 | 0.01 | 0.04 | — | — | — |